Literature DB >> 3523397

Anti-gamete antibodies block transmission of human vivax malaria to mosquitoes.

Y D Munesinghe, K N Mendis, R Carter.   

Abstract

Antibodies were raised in rabbits by immunizing against fresh unfixed or cryopreserved female gametes of the human malaria pathogen Plasmodium vivax. The antibodies were shown to react with the surface of gametes by the indirect immunofluorescent test. When parasite isolates from P. vivax infected individuals were fed through a membrane to Anopheles tessellatus mosquitoes in the presence of immune rabbit sera, they completely blocked the infectivity of the parasite isolates to the vector. Immunoglobulins separated from these sera also blocked infectivity to the same extent as did the immune sera indicating that antibodies were responsible for the transmission blocking effect of the sera. This study indicated that P. vivax like other malaria parasites is highly susceptible to anti gamete transmission blocking immunity.

Entities:  

Mesh:

Year:  1986        PMID: 3523397     DOI: 10.1111/j.1365-3024.1986.tb01035.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  8 in total

1.  Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies.

Authors:  P V Udagama; P H David; J S Peiris; Y G Ariyaratne; K L Perera; K N Mendis
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  Experimental infection of the neotropical malaria vector Anopheles darlingi by human patient-derived Plasmodium vivax in the Peruvian Amazon.

Authors:  Ajay R Bharti; Raul Chuquiyauri; Kimberly C Brouwer; Jeffrey Stancil; Jessica Lin; Alejandro Llanos-Cuentas; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2006-10       Impact factor: 2.345

3.  Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Leonardo Rocha; Diego Alvarez; John C Beier; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

5.  Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans.

Authors:  K N Mendis; Y D Munesinghe; Y N de Silva; I Keragalla; R Carter
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

6.  Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.

Authors:  Thomas C S Martin; Joseph M Vinetz
Journal:  Malar J       Date:  2018-02-21       Impact factor: 2.979

7.  Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector.

Authors:  V A Snewin; S Premawansa; G M Kapilananda; L Ratnayaka; P V Udagama; D M Mattei; E Khouri; G Del Giudice; J S Peiris; K N Mendis; P H David
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

8.  Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential.

Authors:  T S Naotunne; N D Karunaweera; G Del Giudice; M U Kularatne; G E Grau; R Carter; K N Mendis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.